Miller Ruth K
Boston University School of Law, USA.
J Biolaw Bus. 2003;6(2):8-16.
Despite international guidelines and federal regulations, a recent rash of problems in clinical trials have highlighted weaknesses in the oversight process. The federal regulatory system depends on self-policing by researchers and institutions. Because the existing system is overworked, applying common law forms of liability to clinical researchers may encourage improvements in this self-regulation. While research necessarily involves uncertainties, researchers have the greatest direct control over the implementation of the research protocol and the most extensive direct contact with subjects, and must bear corresponding responsibility for acts which fall below the standard of care. This paper argues that the existing FDA patient protections should be adopted as the standards of care for researchers. It examines the possible application of negligence, negligence per se, and fraud and misrepresentation claims against researchers.
尽管有国际准则和联邦法规,但近期一连串的临床试验问题凸显了监督过程中的薄弱环节。联邦监管系统依赖于研究人员和机构的自我监管。由于现有系统工作负担过重,对临床研究人员适用普通法形式的责任可能会促使这种自我监管得到改进。虽然研究必然涉及不确定性,但研究人员对研究方案的实施有最大的直接控制权,并且与受试者有最广泛的直接接触,因此必须对低于护理标准的行为承担相应责任。本文认为,应采用美国食品药品监督管理局(FDA)现有的患者保护措施作为研究人员的护理标准。它探讨了对研究人员提起过失、本身过失以及欺诈和虚假陈述索赔的可能性。